Advertisement

Summit study augurs well for Alzheimer's sufferers

Shares in AIM-listed drug development company Summit rose on Monday after the company unveiled encouraging results from a study investigating the impacts of a treatment on neurodegenerative diseases.

Shares in AIM-listed drug development company Summit rose on Monday after the company unveiled encouraging results from a study investigating the impacts of a treatment on neurodegenerative diseases.

The company reported that it had presented new data from its OGA (O-linked N-acetylglucosaminidase) inhibitor programme for the treatment of tauopathies - a group of neurodegenerative diseases that includes Alzheimer's disease - at the international conference on Alzheimer's and Parkinson's diseases held in Florence from March 6th-to-10th.

Advertisement - Article continues below

It said that OGA inhibitors were evaluated in an in vivo disease model, with results showing "trends to a positive impact on motor impairment symptoms" and improved survival rates following daily oral dosing.

Glyn Edwards, Chief Executive Officer of Summit, commented: "Following the strategic refocusing of Summit to commit all resources into advancing our two clinical-stage programmes, the completion of this study represents the natural conclusion of our involvement in this programme".

"The inhibition of the enzyme OGA has emerged as a potential new treatment paradigm for Alzheimer's disease and related tauopathies. These encouraging results further highlight the promise of the approach and of our OGA inhibitors, and will add greater depth to the scientific data package as we talk with perspective collaborators about taking this programme further into development," he added.

The study evaluated OGA inhibitors, previously identified using Seglin(TM) technology, in a transgenic tauopathy disease model to determine the effect that prolonged dosing had on motor impairments related to the disease and survival rates.

The company reported a clear trend for reduced clasping, a clinical sign indicative of motor impairment, and improved survival rates compared to the untreated cohort. A "statistically significant increase in O-GlcNAcylated protein levels in the brain" was also recorded.

Summit's share price was up 4.17% to 4.38p at 09:20 on Monday morning.

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

An economics lesson from my barber
Inflation

An economics lesson from my barber

On reopening his shop after lockdown, Dominic Frisby’s barber doubled his prices. It’s all part of the post-Covid inflation process – and we’re going …
8 Jul 2020
Three ideas for Lloyds Bank's new boss
UK stockmarkets

Three ideas for Lloyds Bank's new boss

The Black Horse needs whipping into shape. A change at the top provides a great opportunity, says Matthew Lynn.
12 Jul 2020
Why the moving average is my favourite charting tool
Sponsored

Why the moving average is my favourite charting tool

Traders and technical analysts use "moving averages" to iron out daily fluctuations and give a much clearer picture of a market's direction. Dominic …
13 Jul 2020